Wells Fargo & Company Arcellx, Inc. Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ACLX
# of Institutions
179Shares Held
45.9MCall Options Held
53.6KPut Options Held
53.7K-
Perceptive Advisors LLC New York, NY3.89MShares$379 Million6.21% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.85MShares$375 Million8.59% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$365 Million19.51% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$343 Million0.0% of portfolio
-
Sr One Capital Management, LP2.35MShares$229 Million56.87% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $4.27B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...